Cellectar biosciences reports financial results for year ended 2023 and provides a corporate update

Florham park, n.j., march 27, 2024 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended december 31, 2023, and provided a corporate update.

CLRB Ratings Summary

CLRB Quant Ranking